Digilab BioVisioN GmbH Peptidomics Receives United States Patent for Alzheimer's Disease Biomarkers
7/11/2007 12:09:58 PM
HANNOVER, Germany--(BUSINESS WIRE)--Digilab Peptidomics®, formerly BioVisioN, was granted a patent by the US Patent Office for a new panel of biomarkers for the diagnosis of chronic dementia or a predisposition to such diseases. Using proprietary Peptidomics®-Technologies, scientists from Digilab Inc have discovered a group of Osteonpontin marker peptides that correlates to Alzheimer’s Disease, Vascular Dementia, and Parkinson’s Disease. A method for early and reliable detection based on Digilab’s Peptidomics® biomarkers will enable the development of novel therapies for this segment of CNS diseases with debilitating patient care medical consequences.
comments powered by